ES368198A1 - Antibiotic complex - Google Patents
Antibiotic complexInfo
- Publication number
- ES368198A1 ES368198A1 ES368198A ES368198A ES368198A1 ES 368198 A1 ES368198 A1 ES 368198A1 ES 368198 A ES368198 A ES 368198A ES 368198 A ES368198 A ES 368198A ES 368198 A1 ES368198 A1 ES 368198A1
- Authority
- ES
- Spain
- Prior art keywords
- axenomycine
- meoh
- spectrum
- complex
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G11/00—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F7/00—Shielded cells or rooms
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
- G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- General Engineering & Computer Science (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The novel antibiotic axenomycine, also named F.I. 2604, is produced by cultivating Streptomyces lisandri n. sp., I.P.V 1951, I.M.R.U. 3935, I.M.I. 137178, or an axenomycine-producing strain thereof, under aerobic conditions in an aqueous medium containing assimilable sources of carbon and nitrogen and mineral salts, and isolating the axenomycine from the cultivated medium. The cultivation is preferably carried out at 23-37 C. and pH 6-9 for 60-160 hours. Axenomycine is a complex of two components, axenomycines A and B. The complex and its components are amorphous yellowish-white substances, soluble in methyl, ethyl and propyl alcohol, sparingly soluble in water, ethyl acetate, acetone and chloroform, and insoluble in benzene and petroleum ether. They reduce Fehling's solution and ammoniacal silver nitrate, give a positive reaction with tetrazole blue and a weakly positive Molisch reaction. They give negative reactions with ferric chloride, the aniline phthalate test for aldoses and the naphthoresorcinol test for ketoses. Axenomycine A has the following characteristics: elementary analysis, 61.74% C, 8.52% H, 28.87% O molecular weight 1451.3 melting point 127-142 C. to give a transparent reddish gel [[alpha]]23 D = + 10À5 (C = 0.9 in MeOH) Rf = 0.49 on silica gel at pH 7.0 using n. butanol: acetic acid: water = 4: 0.5: 1 U.V. spectrum in MeOH has absorption peaks at 249, 254 and 330 mÁ and a shoulder at 265-268 mÁ I.R. spectrum in a KBr disc has peaks at 2.94, 3À44, 5.78, 6.00, 6.16, 6.24, 6.88, 7.25, 7.41, 8.61, 8.85, 9.35, 10.00, 10.40, 10.95, 11.8 and 12À5 Á. Axenomycine B has the characteristics: elementary analysis, 62.8% C., 8.58% H, 27.8% O molecular weight 1330.2 melting point 122- 140 C. [[alpha]]23 D = + 5 (C = 0.9 in MeOH) Rf = 0À61 on silica gel at pH 7À0 using n. butanol: acetic acid: water = 4À0 : 0À5: 1 U.V. spectrum in MeOH has absorption peaks at 249, 254 and 330 mÁ and a shoulder at 265- 268 mÁ I.R. spectrum in a KBr disc has peaks at 2.94, 3À40, 5.82, 6.00, 6.16, 6.24, 6.86, 7.25, 7.41, 8.60, 8.85, 9.35, 10.00, 10.40, 10.98, 11.8, and 12À5 Á. The antibiotic complex may be extracted from the separated mycelium with e.g. methanol, or from the whole broth with a water-immiscible solvent, and purified by precipitation with a non-solvent followed by counter-current distribution. The two components may be separated by chromatography on a silica gel column at pH 7.0, developing with BuOH: HAc: H 2 O, 4: 0À5: 1 by volume. The antibiotics have anthelmintic, antiprotozoal and antifungal activity. Pharmaceutical compositions comprise axenomycine complex or one of its components A or B together with a pharmaceutically acceptable vehicle.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1757068 | 1968-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES368198A1 true ES368198A1 (en) | 1971-05-01 |
Family
ID=11150434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES368198A Expired ES368198A1 (en) | 1968-06-11 | 1969-06-10 | Antibiotic complex |
Country Status (16)
Country | Link |
---|---|
AT (1) | AT285817B (en) |
BE (1) | BE734341A (en) |
BR (1) | BR6909580D0 (en) |
CH (1) | CH506619A (en) |
CS (1) | CS178807B2 (en) |
DE (1) | DE1929107C3 (en) |
DK (1) | DK120716B (en) |
ES (1) | ES368198A1 (en) |
FR (1) | FR2010640A1 (en) |
GB (1) | GB1219709A (en) |
IE (1) | IE32866B1 (en) |
IL (1) | IL32358A (en) |
NL (1) | NL153271B (en) |
NO (1) | NO127927B (en) |
SE (1) | SE354483B (en) |
YU (1) | YU34212B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1044819B (en) * | 1970-05-04 | 1980-04-21 | Farmaceutici Italia | ANTIBIOTIC COMPOUND |
-
1969
- 1969-05-30 NL NL696908269A patent/NL153271B/en unknown
- 1969-06-06 IE IE769/69A patent/IE32866B1/en unknown
- 1969-06-06 GB GB28849/69A patent/GB1219709A/en not_active Expired
- 1969-06-06 CS CS6900004032A patent/CS178807B2/en unknown
- 1969-06-06 FR FR6918667A patent/FR2010640A1/fr not_active Withdrawn
- 1969-06-06 IL IL32358A patent/IL32358A/en unknown
- 1969-06-09 YU YU1444/69A patent/YU34212B/en unknown
- 1969-06-09 BR BR209580/69A patent/BR6909580D0/en unknown
- 1969-06-09 SE SE08124/69A patent/SE354483B/xx unknown
- 1969-06-09 DK DK310069AA patent/DK120716B/en unknown
- 1969-06-09 AT AT544069A patent/AT285817B/en not_active IP Right Cessation
- 1969-06-09 DE DE1929107A patent/DE1929107C3/en not_active Expired
- 1969-06-09 NO NO02366/69A patent/NO127927B/no unknown
- 1969-06-10 CH CH882169A patent/CH506619A/en not_active IP Right Cessation
- 1969-06-10 BE BE734341D patent/BE734341A/xx unknown
- 1969-06-10 ES ES368198A patent/ES368198A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DE1929107C3 (en) | 1978-10-12 |
NO127927B (en) | 1973-09-03 |
NL6908269A (en) | 1969-12-15 |
IE32866B1 (en) | 1973-12-28 |
DK120716B (en) | 1971-07-05 |
IL32358A (en) | 1972-11-28 |
CH506619A (en) | 1971-04-30 |
GB1219709A (en) | 1971-01-20 |
BE734341A (en) | 1969-12-10 |
IL32358A0 (en) | 1969-08-27 |
FR2010640A1 (en) | 1970-02-20 |
YU34212B (en) | 1979-02-28 |
DE1929107A1 (en) | 1970-02-19 |
IE32866L (en) | 1969-12-11 |
CS178807B2 (en) | 1977-10-31 |
BR6909580D0 (en) | 1973-04-19 |
DE1929107B2 (en) | 1978-02-09 |
YU144469A (en) | 1978-06-30 |
AT285817B (en) | 1970-11-10 |
NL153271B (en) | 1977-05-16 |
SE354483B (en) | 1973-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Grove et al. | The cytotoxicity of some transformation products of diacetoxyscirpenol | |
US3780173A (en) | Partricin methyl ester | |
Hooper et al. | Sesquiterpene hydroquinones from the South African soft coral Alcyonium fauri | |
ES334165A1 (en) | Antibiotic sl 2266 | |
ES368198A1 (en) | Antibiotic complex | |
GB1349179A (en) | Antibiotic | |
GB1038242A (en) | Bleomycin and processes for preparation thereof | |
Kettner et al. | Dactylarin, a new antiprotozoal antibiotic from Dactylaria lutea | |
SE328254B (en) | ||
KITAGAWA et al. | Studies on viomycin. VIII. Selective modifications of the terminal amino groups of viomycin | |
IL42685A (en) | Antibiotic a-2315 and process for preparation thereof | |
Sano et al. | Iyomycin, A New Antitumor Antibiotic from Streptomyces. III Isolation and Properties of Iyomycin B | |
TAKANI et al. | Studies on constituents of medicinal plants. XIX. Constituents of Schizandra nigra Max.(3) | |
US3089816A (en) | Lemacidine and process for its manufacture | |
ES341402A1 (en) | Antibiotics of agricultural fungicides,polyoxins d,e,f,g and h | |
GB1378414A (en) | Antibiotic compound and its preparation | |
GB1314983A (en) | Antibiotic substance and method of producing same | |
ES361544A1 (en) | Process for the production of a new antibiotic sf-733 substance | |
GB1356723A (en) | Antibiotic sf-1293 substance and its production and uses | |
GB1322797A (en) | Antibiotic janiemycin | |
GB1389065A (en) | Process for isolating an antibiotic with both antiprotozoan and cancerostatic activities | |
GB1285163A (en) | Antibiotic compound | |
GB1212741A (en) | A method for producing an antibiotic b-2847 | |
JPS5659777A (en) | Novel antibiotic, xk-213 and its preparation | |
GB1181605A (en) | Libanomycin Antibiotics |